Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications.

Claire E CookNaomi J PatelXiaoqing FuXiaosong WangYumeko KawanoKathleen M M VanniGrace QianEmily BanasiakEmily KowalskiHyon K ChoiYuqing ZhangJeffrey A Sparks Zachary Scott Wallace

Published in: The Journal of rheumatology (2023)

Among patients with SARDs, the risk of breakthrough COVID-19 infection is similar after receiving either BNT162b2 or mRNA-1273. Patients with SARDs initiating the vaccine series should be encouraged to receive whichever mRNA vaccine is available.

Keyphrases

binding protein
multiple sclerosis